United Therapeutics Corporation

    Jurisdiction
    United States
    LEI
    5299005C4HZL4UWROC14
    ISIN
    US91307C1027 (UTHR)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    62 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €553.55 43.8% undervalued
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €2.63B
    Gross margin
    89.0%
    EBIT
    €1.24B
    EBIT margin
    47.0%
    Net income
    €1.06B
    Net margin
    40.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.90B +10.3% €1.15B +8.8%
    €3.04B +4.9% €1.17B +1.8%
    €3.44B +13.4% €1.42B +21.1%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    MAHON PAUL A EVP & GENERAL COUNSEL -11K $385.21 -$4.24M
    BENKOWITZ MICHAEL PRESIDENT AND COO -23K $417.64 -$9.40M
    CAUSEY CHRISTOPHER N/A -3K $423.21 -$1.27M
    MAHON PAUL A EVP & GENERAL COUNSEL -11K $308.75 -$3.40M
    MAHON PAUL A EVP & GENERAL COUNSEL -11K $300.00 -$3.30M

    Congress transactions

    Name Transaction date Value
    Lisa McClain August 13, 2025 $1.00K–$15.00K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.1M $649.52M +18K Buy
    Ray Dalio 194K $59.74M +86K Buy

    Earnings Calls

    Latest earnings call: May 1, 2024 (Q1 2024)

    Add to watchlist

    Notifications